Table 2.

Physical characteristics and particle size distribution of prepared 5-FU-NLC formulation batches (n=3)

Formulation	Average particle size (nm)	PDI	ZP (mV)	EE (%)
5-FU-NLC1	231.21±5.85	0.188±0.042	−21.32±1.2	73.91±2.82
5-FU-NLC2	209.34±6.83	0.363±0.055	−22.51±1.1	71.45±2.45
5-FU-NLC3	213.45±6.32	0.331±0.052	−18.34±0.6	73.52±3.12
5-FU-NLC4	211.23±4.92	0.412±0.065	−21.67±0.7	82.42±3.14
5-FU-NLC5	305.82±5.56	0.512±0.045	−22.82±1.0	84.91±2.12
5-FU-NLC6	212.45±5.31	0.510±0.025	−19.34±0.7	86.62±1.94
5-FU-NLC7	221.23±8.52	0.378±0.064	−21.22±0.9	79.32±1.87
5-FU-NLC8	263.23±6.42	0.412±0.043	−24.91±0.7	83.13±2.21
5-FU-NLC9	309.21±7.12	0.347±0.026	−18.92±0.6	81.25±1.43
5-FU-NLC10	310.59±5.29	0.412±0.048	−19.38±0.5	85.82±2.92
5-FU-NLC11	216.94±4.68	0.332±0.023	−19.45±1.2	85.62±1.23
5-FU-NLC12	210.73±6.42	0.345±0.015	−17.34±0.6	83.51±1.31
Placebo-NLC	202.45±3.84	0.368±0.123	−17.25±1.3	0

Note: Data presented as mean ± standard deviation.

Abbreviations: 5-FU, 5-fluorouracil; NLC, nanostructured lipid carrier; PDI, polydispersity index; ZP, zeta potential; EE, entrapment efficiency.